Seres Therapeutics (MCRB) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free MCRB Stock Alerts $1.16 +0.05 (+4.50%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSeres Therapeutics Incmoney.usnews.com - April 30 at 6:49 PMSeres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTbusinesswire.com - April 9 at 7:00 AMIncreases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for nowfinance.yahoo.com - March 28 at 2:04 PMMCRB Apr 2024 1.000 putfinance.yahoo.com - March 11 at 8:27 AMSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 7 at 2:07 PMSeres Therapeutics price target lowered by $4 at Oppenheimer, here's whyrealmoney.thestreet.com - March 6 at 7:41 PMSeres Therapeutics (MCRB) Gets a Buy from TD Cowenmarkets.businessinsider.com - March 6 at 7:41 PMQ4 2023 Seres Therapeutics Inc Earnings Callfinance.yahoo.com - March 6 at 7:41 PMMCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023investorplace.com - March 5 at 10:31 AMGold Price Alert: Gold Spot Prices Just Hit a Record High Todayinvestorplace.com - March 5 at 10:18 AMSeres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23Mmsn.com - March 5 at 8:53 AMSeres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatesfinance.yahoo.com - March 5 at 8:53 AMSeres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023finance.yahoo.com - March 5 at 8:53 AMSeres Therapeutics's Earnings: A Previewbenzinga.com - March 4 at 12:51 PMSeres Therapeutics Inc MCRBmorningstar.com - March 2 at 11:22 PMSeres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024businesswire.com - February 28 at 7:00 AMSeres Therapeutics to Participate in Cowen 44th Annual Healthcare Conferencefinance.yahoo.com - February 27 at 9:31 AMSeres Therapeutics to Participate in Cowen 44th Annual Healthcare Conferencebusinesswire.com - February 27 at 7:00 AMSeres Therapeutics Appoints Marella Thorell As New CFO Following Retirement Of David Arkowitzmarkets.businessinsider.com - February 26 at 9:47 AMSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitzfinance.yahoo.com - February 26 at 9:47 AMSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitzbusinesswire.com - February 26 at 7:00 AMFederated Hermes Inc. Cuts Position in Seres Therapeutics, Inc. (NASDAQ:MCRB)marketbeat.com - February 25 at 7:16 AMSeres Therapeutics Stock (NASDAQ:MCRB), Short Interest Reportbenzinga.com - February 22 at 8:18 AMNew Seres 3 arrives in the UK priced from £29,995msn.com - February 18 at 6:34 PMMeet the UK's cheapest new electric SUV: the new Seres 3, yours for just under £30kmsn.com - February 18 at 6:34 PMEric D. Shaff Sells 11,549 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) Stockmarketbeat.com - February 17 at 12:43 AMSeres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Updatemarketbeat.com - February 14 at 9:51 AMSell Rating on Seres Therapeutics Amid Underperforming Sales and Financial Challengesmarkets.businessinsider.com - February 7 at 2:58 AMSeres Therapeutics Inc (MCRB)investing.com - February 3 at 10:32 AMSeres Therapeutics Announces 2024 Virtual Stockholders Meetingmsn.com - January 31 at 8:26 AMHuawei’s car-making partner Seres expects reduced 2023 losses, with M7 and M9 EVs paving road to profitabilitymsn.com - January 30 at 8:33 PMShort Interest in Seres Therapeutics, Inc. (NASDAQ:MCRB) Expands By 7.8%marketbeat.com - January 30 at 11:18 AMSeres Therapeutics (NASDAQ:MCRB) Given New $9.00 Price Target at Oppenheimermarketbeat.com - January 16 at 11:25 AMSeres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Drop in Short Interestmarketbeat.com - January 14 at 7:18 AMAnalysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB) and Seres Therapeutics (MCRB)markets.businessinsider.com - January 10 at 7:24 AMWhy Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today?msn.com - January 9 at 2:28 PMSeres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection Treatmentmarketwatch.com - January 9 at 9:28 AMSeres Therapeutics Issues VOWST Commercial Update; Gets Fast Track Designation For SER-155markets.businessinsider.com - January 9 at 9:28 AMSeres Therapeutics reports VOWST prelim. Q4 sales of $10.4M; shares jumpmsn.com - January 9 at 9:28 AMSeres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155finance.yahoo.com - January 9 at 9:28 AMSeres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 4 at 4:49 PMSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of "Moderate Buy" from Brokeragesmarketbeat.com - January 2 at 2:20 AMMCRB Jan 2026 1.500 callca.finance.yahoo.com - December 18 at 8:32 AMMCRB Jan 2026 1.500 putca.finance.yahoo.com - December 18 at 8:32 AMSeres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023finance.yahoo.com - December 8 at 12:37 AMSeres Therapeutics, Inc. (NASDAQ:MCRB) is a favorite amongst institutional investors who own 62%finance.yahoo.com - December 2 at 1:48 PMSeres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ETfinance.yahoo.com - November 28 at 2:11 PMSeres Therapeutics: Evaluating Vowst's Market Challenges (Rating Downgrade)seekingalpha.com - November 15 at 12:45 AMSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Seres Therapeutics, Inc. (NASDAQ: MCRB) and Encourages Investors to Contact the Firmbenzinga.com - November 11 at 10:50 AMSeres cuts its workforce by nearly half, focuses on FDA-approved drugbizjournals.com - November 6 at 2:32 PM Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Watch this FREE trading tutorial while it’s still available (Ad)On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges. Click here for details. MCRB Media Mentions By Week MCRB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MCRB News Sentiment▼0.290.43▲Average Medical News Sentiment MCRB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MCRB Articles This Week▼11▲MCRB Articles Average Week Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RZLT News Today CTMX News Today SCTL News Today ADAG News Today NVCT News Today COYA News Today PDSB News Today INCR News Today RLMD News Today IMUX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MCRB) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
